| langue originale | Anglais |
|---|---|
| Pages (de - à) | 123-125 |
| Nombre de pages | 3 |
| journal | Annals of Oncology |
| Volume | 33 |
| Numéro de publication | 2 |
| Les DOIs | |
| état | Publié - 1 févr. 2022 |
| Modification externe | Oui |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Annals of Oncology, Vol 33, Numéro 2, 01.02.2022, p. 123-125.
Résultats de recherche: Contribution à un journal › Editorial
TY - JOUR
T1 - Malignant pleural mesothelioma
T2 - new guidelines make us stronger for defeating this disease
AU - Remon, J.
AU - Hendriks, L. E.L.
AU - Bironzo, P.
N1 - Funding Information: None declared. JR none related to current manuscript, outside of current manuscript: advisory board: Merck Sharp & Dohme (MSD), Boehringer Ingelheim, Bristol Myers Squibb (BMS), AstraZeneca, Roche, Bayer. Speaker: Pfizer; travel reimbursement: Ose Immunotherapeutics, BMS, AstraZeneca, Roche. LH none related to current manuscript, outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, Takeda and Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. PB none related to current manuscript, outside of current manuscript: honoraria: AstraZeneca, Roche, BMS, Beigene, Takeda. Institutional grant: Roche, Pfizer. Travel grants: Amgen, Daiichi Sankyo. Funding Information: JR none related to current manuscript, outside of current manuscript: advisory board: Merck Sharp & Dohme (MSD), Boehringer Ingelheim, Bristol Myers Squibb (BMS), AstraZeneca, Roche, Bayer. Speaker: Pfizer; travel reimbursement: Ose Immunotherapeutics, BMS, AstraZeneca, Roche. LH none related to current manuscript, outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, Takeda and Beigene under negotiation); advisory board: BMS, Eli Lilly, Roche Genentech, Pfizer, Takeda, MSD, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: MSD, Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), interview sessions funded by Roche Genentech, Bayer, Lilly (institution); local PI of clinical trials: AstraZeneca, Novartis, BMS, MSD/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. PB none related to current manuscript, outside of current manuscript: honoraria: AstraZeneca, Roche, BMS, Beigene, Takeda. Institutional grant: Roche, Pfizer. Travel grants: Amgen, Daiichi Sankyo.
PY - 2022/2/1
Y1 - 2022/2/1
UR - http://www.scopus.com/inward/record.url?scp=85121217147&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.11.019
DO - 10.1016/j.annonc.2021.11.019
M3 - Editorial
C2 - 34883215
AN - SCOPUS:85121217147
SN - 0923-7534
VL - 33
SP - 123
EP - 125
JO - Annals of Oncology
JF - Annals of Oncology
IS - 2
ER -